Table of Content

1. Executive Summary
   1.1. Global Antiviral Drugs Market Snapshot, 2024 and 2031
   1.2. Market Opportunity Assessment, 2024 - 2031, US$ Mn
   1.3. Key Market Trends
   1.4. Future Market Projections
   1.5. Premium Market Insights
   1.6. Industry Developments and Key Market Events
   1.7. PMR Analysis and Recommendations
2. Market Overview
   2.1. Market Scope and Definition
   2.2. Market Dynamics
       2.2.1. Drivers
       2.2.2. Restraints
       2.2.3. Opportunity
       2.2.4. Challenges
       2.2.5. Key Trends
   2.3. Macro-Economic Factors
       2.3.1. Global Sectorial Outlook
       2.3.2. Global GDP Growth Outlook
       2.3.3. Global Healthcare Spending Outlook
   2.4. COVID-19 Impact Analysis
   2.5. Forecast Factors - Relevance and Impact
3. Value Added Insights
   3.1. Regulatory Landscape
   3.2. Product Adoption Analysis
   3.3. Key Promotional Strategies by Manufacturer
   3.4. Value Chain Analysis
   3.5. Key Deals and Mergers
   3.6. PESTLE Analysis
   3.7. Porter’s Five Force Analysis
4. Global Antiviral Drugs Market Outlook: Historical (2018 - 2022) and Forecast (2024 - 2031)
   4.1. Key Highlights
       4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
       4.1.2. Absolute $ Opportunity
   4.2. Market Size (US$ Mn) Analysis and Forecast
       4.2.1. Historical Market Size (US$ Mn) Analysis, 2018-2022
       4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2023-2031
   4.3. Global Antiviral Drugs Market Outlook: Drug Class
       4.3.1. Introduction / Key Findings
       4.3.2. Historical Market Size (US$ Mn) Analysis, By Drug Class, 2018 - 2022
       4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2023 - 2031
           4.3.3.1. DNA Polymerase Inhibitors
           4.3.3.2. Reverse Transcriptase Inhibitors
           4.3.3.3. Protease Inhibitors
           4.3.3.4. Neuraminidase Inhibitors
           4.3.3.5. Others
       4.3.4. Market Attractiveness Analysis: Drug Class
   4.4. Global Antiviral Drugs Market Outlook: Type
       4.4.1. Introduction / Key Findings
       4.4.2. Historical Market Size (US$ Mn) Analysis, By Type, 2018 - 2022
       4.4.3. Current Market Size (US$ Mn) Analysis and Forecast, By Type, 2023 - 2031
           4.4.3.1. Branded
           4.4.3.2. Generics
       4.4.4. Market Attractiveness Analysis: Type
   4.5. Global Antiviral Drugs Market Outlook: Application
       4.5.1. Introduction / Key Findings
       4.5.2. Historical Market Size (US$ Mn) Analysis, By Application, 2018 - 2022
       4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2023 - 2031
           4.5.3.1. HIV
           4.5.3.2. Hepatitis
           4.5.3.3. Herpes
           4.5.3.4. Influenza
           4.5.3.5. Others
       4.5.4. Market Attractiveness Analysis: Application
5. Global Antiviral Drugs Market Outlook: Region
   5.1. Key Highlights
   5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2018 - 2022
   5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2023 - 2031
       5.3.1. North America
       5.3.2. Europe
       5.3.3. East Asia
       5.3.4. South Asia and Oceania
       5.3.5. Latin America
       5.3.6. Middle East & Africa
   5.4. Market Attractiveness Analysis: Region
6. North America Antiviral Drugs Market Outlook: Historical (2018 - 2022) and Forecast (2024 - 2031)
   6.1. Key Highlights
   6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2018 - 2022
       6.2.1. By Country
       6.2.2. By Drug Class
       6.2.3. By Type
       6.2.4. By Application
   6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2023 - 2031
       6.3.1. U.S.
       6.3.2. Canada
   6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2023 - 2031
       6.4.1. DNA Polymerase Inhibitors
       6.4.2. Reverse Transcriptase Inhibitors
       6.4.3. Protease Inhibitors
       6.4.4. Neuraminidase Inhibitors
       6.4.5. Others
   6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Type, 2023 - 2031
       6.5.1. Branded
       6.5.2. Generics
   6.6. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2023 - 2031
       6.6.1. HIV
       6.6.2. Hepatitis
       6.6.3. Herpes
       6.6.4. Influenza
       6.6.5. Others
   6.7. Market Attractiveness Analysis
7. Europe Antiviral Drugs Market Outlook: Historical (2018 - 2022) and Forecast (2024 - 2031)
   7.1. Key Highlights
   7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2018 - 2022
       7.2.1. By Country
       7.2.2. By Drug Class
       7.2.3. By Type
       7.2.4. By Application
   7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2023 - 2031
       7.3.1. Germany
       7.3.2. France
       7.3.3. U.K.
       7.3.4. Italy
       7.3.5. Spain
       7.3.6. Russia
       7.3.7. Türkiye
       7.3.8. Rest of Europe
   7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2023 - 2031
       7.4.1. DNA Polymerase Inhibitors
       7.4.2. Reverse Transcriptase Inhibitors
       7.4.3. Protease Inhibitors
       7.4.4. Neuraminidase Inhibitors
       7.4.5. Others
   7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Type, 2023 - 2031
       7.5.1. Branded
       7.5.2. Generics
   7.6. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2023 - 2031
       7.6.1. HIV
       7.6.2. Hepatitis
       7.6.3. Herpes
       7.6.4. Influenza
       7.6.5. Others
   7.7. Market Attractiveness Analysis
8. East Asia Antiviral Drugs Market Outlook: Historical (2018 - 2022) and Forecast (2024 - 2031)
   8.1. Key Highlights
   8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2018 - 2022
       8.2.1. By Country
       8.2.2. By Drug Class
       8.2.3. By Type
       8.2.4. By Application
   8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2023 - 2031
       8.3.1. China
       8.3.2. Japan
       8.3.3. South Korea
   8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2023 - 2031
       8.4.1. DNA Polymerase Inhibitors
       8.4.2. Reverse Transcriptase Inhibitors
       8.4.3. Protease Inhibitors
       8.4.4. Neuraminidase Inhibitors
       8.4.5. Others
   8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Type, 2023 - 2031
       8.5.1. Branded
       8.5.2. Generics
   8.6. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2023 - 2031
       8.6.1. HIV
       8.6.2. Hepatitis
       8.6.3. Herpes
       8.6.4. Influenza
       8.6.5. Others
   8.7. Market Attractiveness Analysis
9. South Asia & Oceania Antiviral Drugs Market Outlook: Historical (2018 - 2022) and Forecast (2024 - 2031)
   9.1. Key Highlights
   9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2018 - 2022
       9.2.1. By Country
       9.2.2. By Drug Class
       9.2.3. By Type
       9.2.4. By Application
   9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2023 - 2031
       9.3.1. India
       9.3.2. Southeast Asia
       9.3.3. ANZ
       9.3.4. Rest of South Asia & Oceania
   9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2023 - 2031
       9.4.1. DNA Polymerase Inhibitors
       9.4.2. Reverse Transcriptase Inhibitors
       9.4.3. Protease Inhibitors
       9.4.4. Neuraminidase Inhibitors
       9.4.5. Others
   9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Type, 2023 - 2031
       9.5.1. Branded
       9.5.2. Generics
   9.6. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2023 - 2031
       9.6.1. HIV
       9.6.2. Hepatitis
       9.6.3. Herpes
       9.6.4. Influenza
       9.6.5. Others
   9.7. Market Attractiveness Analysis
10. Latin America Antiviral Drugs Market Outlook: Historical (2018 - 2022) and Forecast (2024 - 2031)
   10.1. Key Highlights
   10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2018 - 2022
       10.2.1. By Country
       10.2.2. By Drug Class
       10.2.3. By Type
       10.2.4. By Application
   10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2023 - 2031
       10.3.1. Brazil
       10.3.2. Mexico
       10.3.3. Rest of Latin America
   10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2023 - 2031
       10.4.1. DNA Polymerase Inhibitors
       10.4.2. Reverse Transcriptase Inhibitors
       10.4.3. Protease Inhibitors
       10.4.4. Neuraminidase Inhibitors
       10.4.5. Others
   10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Type, 2023 - 2031
       10.5.1. Branded
       10.5.2. Generics
   10.6. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2023 - 2031
       10.6.1. HIV
       10.6.2. Hepatitis
       10.6.3. Herpes
       10.6.4. Influenza
       10.6.5. Others
   10.7. Market Attractiveness Analysis
11. Middle East & Africa Antiviral Drugs Market Outlook: Historical (2018 - 2022) and Forecast (2024 - 2031)
   11.1. Key Highlights
   11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2018 - 2022
       11.2.1. By Country
       11.2.2. By Drug Class
       11.2.3. By Type
       11.2.4. By Application
   11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2023 - 2031
       11.3.1. GCC Countries
       11.3.2. Egypt
       11.3.3. South Africa
       11.3.4. Northern Africa
       11.3.5. Rest of Middle East & Africa
   11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Drug Class, 2023 - 2031
       11.4.1. DNA Polymerase Inhibitors
       11.4.2. Reverse Transcriptase Inhibitors
       11.4.3. Protease Inhibitors
       11.4.4. Neuraminidase Inhibitors
       11.4.5. Others
   11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Type, 2023 - 2031
       11.5.1. Branded
       11.5.2. Generics
   11.6. Current Market Size (US$ Mn) Analysis and Forecast, By Application, 2023 - 2031
       11.6.1. HIV
       11.6.2. Hepatitis
       11.6.3. Herpes
       11.6.4. Influenza
       11.6.5. Others
   11.7. Market Attractiveness Analysis
12. Competition Landscape
   12.1. Market Share Analysis, 2023
   12.2. Market Structure
       12.2.1. Competition Intensity Mapping By Market
       12.2.2. Competition Dashboard
   12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
       12.3.1. F. Hoffmann-La Roche Ltd.
           12.3.1.1. Overview
           12.3.1.2. Segments and Products
           12.3.1.3. Key Financials
           12.3.1.4. Market Developments
           12.3.1.5. Market Strategy
       12.3.2. GlaxoSmithKline plc
       12.3.3. AbbVie
       12.3.4. Merck & Co., Inc.
       12.3.5. Johnson & Johnson Services, Inc.
       12.3.6. Bristol-Myers Squibb Company
       12.3.7. Cipla Inc.
       12.3.8. Aurobindo Pharma
       12.3.9. Dr. Reddy’s Laboratories Ltd.
13. Appendix
   13.1. Research Methodology
   13.2. Research Assumptions
   13.3. Acronyms and Abbreviations